ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited
2
Statement of Financial Position
3
As at 30 June 2026
4
5
6
Consolidated
Separate
7
financial information
financial information
8
UnauditedAuditedUnauditedAudited
9
30 June
31 December
30 June
31 December
10
2026202520262025
11
NotesBaht’000Baht’000Baht’000Baht’000
12
13
Assets
14
15
Current assets
16
17
Cash and cash equivalents
42,83948,03114,59318,565
18
Trade accounts receivable, net
8131,962151,38379,916101,413
19
Other current receivables, net
26,13526,80950,15743,854
20
Short-term loans to related parties
17.3--69,80069,800
21
Current portion of long-term loan to
22
a related party, net
17.3----
23
Inventories, net
9119,999101,439103,16689,498
24
25
Total current assets
320,935327,662317,632323,130
26
27
Non-current assets
28
29
Deposits at financial institution used as collaterals
6,2016,1464,6514,610
30
Investment in subsidiaries, net
10--132,66193,149
31
Investment in an associate, net
----
32
Advance shares subscription payment
10---39,512
33
Other non-current receivables
337675--
34
Property, plant and equipment, net
111,053,3401,071,784913,486926,148
35
Goodwill
32,55132,551--
36
Intangible assets, net
4,2544,5123,6433,683
37
Deferred tax assets, net
19,74017,90735,74235,272
38
Other non-current assets
2,0382,3171,044829
39
40
Total non-current assets
1,118,4611,135,8921,091,2271,103,203
41
42
Total assets
1,439,3961,463,5541,408,8591,426,333
43
44
45
46
47
48
49
Director ……………………………………………………………….
Director ……………………………………………………………….
50
51
52
The accompanying condensed notes to the interim financial information are an integral part of this interim financial information.
53
JSP Pharmaceutical Manufacturing (Thailand) Public Company Limited
54
Statement of Financial Position
55
As at 30 June 2026
56
57
58
Consolidated
Separate
59
financial information
financial information
60
UnauditedAuditedUnauditedAudited
61
30 June
31 December
30 June
31 December
62
2026202520262025
63
NotesBaht’000Baht’000Baht’000Baht’000
64
65
Liabilities and equity
66
67
Current liabilities
68
69
Bank overdrafts and short-term loans from
70
financial institutions
1280,99347,84269,95138,997
71
Trade accounts payable
58,25945,84535,66226,561
72
Current contract liabilities
12,51015,4389,45313,621
73
Other current payables
34,49555,22821,91640,050
74
Short-term loans from related parties
17.3-5,000--
75
Current portion of long-term loans
76
from financial institutions, net
1345,07444,35345,07444,353
77
Current portion of lease liabilities, net
1416,13611,9175,1794,918
78
Corporate income tax payable
4,59410,9154,0419,519
79
80
Total current liabilities
252,061236,538191,276178,019
81
82
Non-current liabilities
83
84
Long-term loans from financial institutions, net
13209,814232,590209,814232,590
85
Lease liabilities, net
1436,01139,4678,2146,986
86
Non-current contract liabilities
4,5126,6284,5126,628
87
Employee benefit obligations
20,30919,92616,12116,161
88
Deferred tax liabilities, net
41157--
89
Other non-current provisions
1,2761,2521,2761,252
90
91
Total non-current liabilities
271,963300,020239,937263,617
92
93
Total liabilities
524,024536,558431,213441,636
94
95
96
97
98
99
100